Vimarsana
Biggest News Aggregation in the World

Acta Myol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acta Myol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acta Myol Today - Breaking & Trending Today

McArdle Disease - Symptoms - Diagnosis -Treatment - Vimarsana News

McArdle Disease - Symptoms - Diagnosis -Treatment

McArdle disease is a genetic disorder in which the body cannot breakdown glycogen in the muscles. It also known as McArdle syndrome or Glycogen storage disease type V (GSD-V).

What is McArdle's Disease? - Vimarsana News

What is McArdle's Disease?

McArdle’s disease, also known as Glycogen Storage Disease Type V, or GSD5, is a congenital disorder of muscle metabolism. This article discusses the disease in more detail.

Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy - Vimarsana News

Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA). This Phase 2 pilot study is a randomized, double-blind ...

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy - Vimarsana News

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot

Frontiers | The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection - Vimarsana News

Frontiers | The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection

COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has been drastically affecting the daily lives of millions of people. COVID-19 is described as a multiorgan disease that affects not only the respiratory tract of infected individuals, but it has considerable effects on the musculoskeletal system, causing excessive fatigue, myalgia, arthralgia, muscle weakness and skeletal muscle damage. These symptoms can persist for months, decreasing the quality of life of numerous individuals. Curiously, most studies in the scientific literature focus on patients who were hospitalized due to S...